The novel gluconeogenesis inhibitor FR225654 that originates from Phoma sp. no. 00144. II. Biological activities.
The novel gluconeogenesis inhibitor FR225654, isolated from the culture broth of Phoma sp. No. 00144, has an unique structure that consists of a highly oxygenated trans-decalin ring and a beta-keto-enol, with a characteristic side chain. This compound selectively inhibited gluconeogenesis of rat primary hepatocytes and had hypoglycemic effects in several in vivo mouse models.
Ohtsu
Yoshihiro
Y
Fermentation Research Laboratories, Fujisawa Pharmaceutical Co, Ltd. yoshihiro.ohtsu@jp.astellas.com
Sasamura
Hiromi
H
Shibata
Toshihiro
T
Hino
Motohiro
M
Nakajima
Hidenori
H
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D005943:Gluconeogenesis / Q000187:drug effects*; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats
D001786:Blood Glucose; C504133:FR225654; D007004:Hypoglycemic Agents; D009281:Naphthalenes